XENON PHARMACEUTICALS INC. Research and Development Expense
XENON PHARMACEUTICALS INC. (XENE) reported Research and Development Expense of $99.22 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- XENON PHARMACEUTICALS INC. research and development expense for the quarter ending 2026-06-30 was $99.22M, a 32.33% increase year-over-year.
- XENON PHARMACEUTICALS INC. research and development expense for the quarter ending 2026-03-31 was $88.51M, a 44.62% increase year-over-year.
- XENON PHARMACEUTICALS INC. research and development expense for the quarter ending 2025-12-31 was $87.70M, a 47.46% increase year-over-year.
- XENON PHARMACEUTICALS INC. research and development expense for the quarter ending 2025-09-30 was $77.05M, a 35.25% increase year-over-year.
- XENON PHARMACEUTICALS INC. research and development expense for fiscal 2025 was $300.94M, a 43.04% increase from fiscal 2024.
- XENON PHARMACEUTICALS INC. research and development expense for fiscal 2024 was $210.39M, a 25.60% increase from fiscal 2023.
- XENON PHARMACEUTICALS INC. research and development expense for fiscal 2023 was $167.51M, a 58.38% increase from fiscal 2022.
- XENON PHARMACEUTICALS INC. research and development expense for fiscal 2022 was $105.77M, a 40.16% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $99.22M 10-Q · filed 2026-08-06 | $187.73M 10-Q · filed 2026-08-06 | $275.43M derived: sum of 3 quarters · filed 2026-08-06 | $352.49M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $88.51M 10-Q · filed 2026-05-07 | $176.21M derived: sum of 2 quarters · filed 2026-05-07 | $253.26M derived: sum of 3 quarters · filed 2026-05-07 | $328.25M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | $87.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $164.75M derived: sum of 2 quarters · filed 2026-02-26 | $239.74M derived: sum of 3 quarters · filed 2026-08-06 | $300.94M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $77.05M 10-Q · filed 2025-11-03 | $152.04M derived: sum of 2 quarters · filed 2026-08-06 | $213.24M 10-Q · filed 2025-11-03 | $272.71M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $74.98M 10-Q · filed 2026-08-06 | $136.19M 10-Q · filed 2026-08-06 | $195.66M derived: sum of 3 quarters · filed 2026-08-06 | $252.63M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $61.20M 10-Q · filed 2026-05-07 | $120.67M derived: sum of 2 quarters · filed 2026-05-07 | $177.64M derived: sum of 3 quarters · filed 2026-05-07 | $227.34M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $59.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $116.44M derived: sum of 2 quarters · filed 2026-02-26 | $166.14M derived: sum of 3 quarters · filed 2026-02-26 | $210.39M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $56.97M 10-Q · filed 2025-11-03 | $106.67M derived: sum of 2 quarters · filed 2025-11-03 | $150.92M 10-Q · filed 2025-11-03 | $192.00M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-06-30 | $49.70M 10-Q · filed 2025-08-11 | $93.95M 10-Q · filed 2025-08-11 | $135.03M derived: sum of 3 quarters · filed 2026-02-26 | $177.91M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-03-31 | $44.25M 10-Q · filed 2025-05-12 | $85.33M derived: sum of 2 quarters · filed 2026-02-26 | $128.21M derived: sum of 3 quarters · filed 2026-02-26 | $172.25M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | $41.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $83.96M derived: sum of 2 quarters · filed 2026-02-26 | $128.00M derived: sum of 3 quarters · filed 2026-02-26 | $167.51M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $42.88M 10-Q · filed 2024-11-12 | $86.92M derived: sum of 2 quarters · filed 2024-11-12 | $126.44M 10-Q · filed 2024-11-12 | $161.27M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-06-30 | $44.04M 10-Q · filed 2024-08-08 | $83.56M 10-Q · filed 2024-08-08 | $118.39M derived: sum of 3 quarters · filed 2025-02-27 | $147.82M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-03-31 | $39.52M 10-Q · filed 2024-05-09 | $74.35M derived: sum of 2 quarters · filed 2025-02-27 | $103.78M derived: sum of 3 quarters · filed 2025-02-27 | $125.92M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2022-12-31 | $34.83M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $64.26M derived: sum of 2 quarters · filed 2025-02-27 | $86.41M derived: sum of 3 quarters · filed 2025-02-27 | $105.77M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $29.43M 10-Q · filed 2023-11-08 | $51.58M derived: sum of 2 quarters · filed 2023-11-08 | $70.94M 10-Q · filed 2023-11-08 | $92.82M derived: sum of 4 quarters · filed 2024-02-29 | |||
| 2022-06-30 | $22.15M 10-Q · filed 2023-08-09 | $41.51M 10-Q · filed 2023-08-09 | $63.39M derived: sum of 3 quarters · filed 2024-02-29 | $82.28M derived: sum of 4 quarters · filed 2024-02-29 | |||
| 2022-03-31 | $19.36M 10-Q · filed 2023-05-09 | $41.25M derived: sum of 2 quarters · filed 2024-02-29 | $60.14M derived: sum of 3 quarters · filed 2024-02-29 | $78.52M derived: sum of 4 quarters · filed 2024-02-29 | |||
| 2021-12-31 | $21.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $40.78M derived: sum of 2 quarters · filed 2024-02-29 | $59.16M derived: sum of 3 quarters · filed 2024-02-29 | $75.46M 10-K · filed 2024-02-29 | |||
| 2021-09-30 | $18.89M 10-Q · filed 2022-11-08 | $37.27M derived: sum of 2 quarters · filed 2022-11-08 | $53.58M 10-Q · filed 2022-11-08 | $68.54M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2021-06-30 | $18.38M 10-Q · filed 2022-08-09 | $34.69M 10-Q · filed 2022-08-09 | $49.65M derived: sum of 3 quarters · filed 2023-03-01 | $62.70M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2021-03-31 | $16.31M 10-Q · filed 2022-05-10 | $31.27M derived: sum of 2 quarters · filed 2023-03-01 | $44.32M derived: sum of 3 quarters · filed 2023-03-01 | $55.04M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2020-12-31 | $14.97M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $28.01M derived: sum of 2 quarters · filed 2023-03-01 | $38.73M derived: sum of 3 quarters · filed 2023-03-01 | $50.52M 10-K · filed 2023-03-01 | |||
| 2020-09-30 | $13.04M 10-Q · filed 2021-11-10 | $23.77M derived: sum of 2 quarters · filed 2021-11-10 | $35.56M 10-Q · filed 2021-11-10 | $47.31M derived: sum of 4 quarters · filed 2021-11-10 | |||
| 2020-06-30 | $10.72M 10-Q · filed 2021-08-11 | $22.51M 10-Q · filed 2021-08-11 | $34.26M derived: sum of 3 quarters · filed 2021-08-11 | $44.01M derived: sum of 4 quarters · filed 2021-08-11 | |||
| 2020-03-31 | $11.79M 10-Q · filed 2021-05-11 | $23.54M derived: sum of 2 quarters · filed 2021-05-11 | $33.29M derived: sum of 3 quarters · filed 2021-05-11 | $41.50M derived: sum of 4 quarters · filed 2021-05-11 | |||
| 2019-12-31 | $11.75M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $21.50M derived: sum of 2 quarters · filed 2021-03-01 | $29.71M derived: sum of 3 quarters · filed 2021-03-01 | $38.84M 10-K · filed 2021-03-01 | |||
| 2019-09-30 | $9.75M 10-Q · filed 2020-11-05 | $17.96M derived: sum of 2 quarters · filed 2020-11-05 | $27.09M 10-Q · filed 2020-11-05 | $33.49M derived: sum of 4 quarters · filed 2020-11-05 | |||
| 2019-06-30 | $8.21M 10-Q · filed 2020-08-06 | $17.34M 10-Q · filed 2020-08-06 | $23.74M derived: sum of 3 quarters · filed 2020-08-06 | $29.99M derived: sum of 4 quarters · filed 2020-08-06 | |||
| 2019-03-31 | $9.14M 10-Q/A · filed 2020-05-26 | $15.54M derived: sum of 2 quarters · filed 2020-05-26 | $21.79M derived: sum of 3 quarters · filed 2020-05-26 | $27.20M derived: sum of 4 quarters · filed 2020-05-26 | |||
| 2018-12-31 | $6.40M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | $12.65M derived: sum of 2 quarters · filed 2020-03-09 | $18.07M derived: sum of 3 quarters · filed 2020-03-09 | $23.63M 10-K · filed 2020-03-09 | |||
| 2018-09-30 | $6.25M 10-Q · filed 2019-11-05 | $6.24M 10-Q · filed 2018-11-06 | $11.66M derived: sum of 2 quarters · filed 2019-11-05 | $17.23M 10-Q · filed 2019-11-05 | $17.23M 10-Q · filed 2018-11-06 | $23.63M derived: sum of 4 quarters · filed 2019-11-05 | |
| 2018-06-30 | $5.42M 10-Q · filed 2019-08-06 | $5.41M 10-Q · filed 2018-08-07 | $10.98M 10-Q · filed 2019-08-06 | $10.99M 10-Q · filed 2018-08-07 | $17.38M derived: sum of 3 quarters · filed 2019-08-06 | $24.55M derived: sum of 4 quarters · filed 2019-08-06 | |
| 2018-03-31 | $5.57M 10-Q · filed 2019-05-07 | $5.58M 10-Q · filed 2018-05-08 | $11.96M derived: sum of 2 quarters · filed 2019-05-07 | $19.13M derived: sum of 3 quarters · filed 2019-05-07 | $25.24M derived: sum of 4 quarters · filed 2019-05-07 | ||
| 2017-12-31 | $6.40M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $13.56M derived: sum of 2 quarters · filed 2019-03-06 | $19.67M derived: sum of 3 quarters · filed 2019-03-06 | $25.57M 10-K · filed 2019-03-06 | |||
| 2017-09-30 | $7.16M 10-Q · filed 2018-11-06 | $13.27M derived: sum of 2 quarters · filed 2018-11-06 | $19.18M 10-Q · filed 2018-11-06 | $23.57M derived: sum of 4 quarters · filed 2018-11-06 | |||
| 2017-06-30 | $6.11M 10-Q · filed 2018-08-07 | $12.01M 10-Q · filed 2018-08-07 | $16.41M derived: sum of 3 quarters · filed 2018-08-07 | $22.37M derived: sum of 4 quarters · filed 2018-08-07 | |||
| 2017-03-31 | $5.90M 10-Q · filed 2018-05-08 | $10.30M derived: sum of 2 quarters · filed 2018-05-08 | $16.26M derived: sum of 3 quarters · filed 2018-05-08 | $21.37M derived: sum of 4 quarters · filed 2018-05-08 | |||
| 2016-12-31 | $4.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $10.36M derived: sum of 2 quarters · filed 2018-03-07 | $15.46M derived: sum of 3 quarters · filed 2018-03-07 | $19.83M 10-K · filed 2018-03-07 | |||
| 2016-09-30 | $5.96M 10-Q · filed 2017-11-07 | $11.07M derived: sum of 2 quarters · filed 2017-11-07 | $15.43M 10-Q · filed 2017-11-07 | $19.70M derived: sum of 4 quarters · filed 2018-03-07 | |||
| 2016-06-30 | $5.10M 10-Q · filed 2017-08-03 | $9.47M 10-Q · filed 2017-08-03 | $13.73M derived: sum of 3 quarters · filed 2018-03-07 | $17.52M derived: sum of 4 quarters · filed 2018-03-07 | |||
| 2016-03-31 | $4.36M 10-Q · filed 2017-05-09 | $8.63M derived: sum of 2 quarters · filed 2018-03-07 | $12.42M derived: sum of 3 quarters · filed 2018-03-07 | $16.09M derived: sum of 4 quarters · filed 2018-03-07 | |||
| 2015-12-31 | $4.26M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $8.06M derived: sum of 2 quarters · filed 2018-03-07 | $11.72M derived: sum of 3 quarters · filed 2018-03-07 | $15.15M 10-K · filed 2018-03-07 | |||
| 2015-09-30 | $3.79M 10-Q · filed 2016-11-03 | $7.46M derived: sum of 2 quarters · filed 2016-11-03 | $10.89M 10-Q · filed 2016-11-03 | $14.34M derived: sum of 4 quarters · filed 2017-03-08 | |||
| 2015-06-30 | $3.67M 10-Q · filed 2016-08-03 | $7.10M 10-Q · filed 2016-08-03 | $10.55M derived: sum of 3 quarters · filed 2017-03-08 | $13.77M derived: sum of 4 quarters · filed 2017-03-08 | |||
| 2015-03-31 | $3.43M 10-Q · filed 2016-05-10 | $6.88M derived: sum of 2 quarters · filed 2017-03-08 | $10.10M derived: sum of 3 quarters · filed 2017-03-08 | $12.66M derived: sum of 4 quarters · filed 2017-03-08 | |||
| 2014-12-31 | $3.45M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-08 | $6.67M derived: sum of 2 quarters · filed 2017-03-08 | $9.23M derived: sum of 3 quarters · filed 2017-03-08 | $11.77M 10-K · filed 2017-03-08 | |||
| 2014-09-30 | $3.22M 10-Q · filed 2015-11-10 | $5.78M derived: sum of 2 quarters · filed 2015-11-10 | $8.31M 10-Q · filed 2015-11-10 | $11.06M derived: sum of 4 quarters · filed 2016-03-08 | |||
| 2014-06-30 | $2.57M 10-Q · filed 2015-08-13 | $5.10M 10-Q · filed 2015-08-13 | $7.84M derived: sum of 3 quarters · filed 2016-03-08 | $10.42M derived: sum of 4 quarters · filed 2016-03-08 | |||
| 2014-03-31 | $2.53M 10-Q/A · filed 2015-08-13 | $5.28M derived: sum of 2 quarters · filed 2016-03-08 | $7.85M derived: sum of 3 quarters · filed 2016-03-08 | ||||
| 2013-12-31 | $2.74M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-08 | $5.32M derived: sum of 2 quarters · filed 2016-03-08 | $12.30M 10-K · filed 2016-03-08 | ||||
| 2013-09-30 | $2.58M 10-Q · filed 2014-12-15 | $9.56M 10-Q · filed 2014-12-15 | |||||
| 2012-12-31 | $10.46M 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |